New eye drop shows promise for rare corneal disease
NCT ID NCT04485546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an eye drop called OXERVATE in 37 adults with stage 1 neurotrophic keratitis, a condition where the cornea loses feeling and doesn't heal properly. The treatment was given for 8 weeks, and patients were followed for 24 weeks to see if the cornea healed safely. The main goal was to check how many patients had complete corneal healing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston
Boston, Massachusetts, 02111, United States
-
Edgewood
Edgewood, Kentucky, 41017, United States
-
Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Saint Louis
St Louis, Missouri, 63131, United States
-
San Diego
San Diego, California, 92122, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New eye drops show promise for healing corneal damage
- New eye drops aim to heal damaged corneas
- New eye drop shows promise for rare corneal disease
- New eye drops aim to heal corneal damage and restore sensation
- Gene therapy eye drops aim to heal corneas in rare nerve disorder
- Could a simple ingredient boost dry eye drops?